A Killer Of Superbugs
Better than antibiotics, it is being used in contact lenses to prevent infections and biomedical products are the next stage The superbugs have met their match. Conceived at Nanyang Technological University (NTU), it comes in the form of a coating which has a magnetic-like feature that attracts bacteria and kills them without the need for antibiotics...
Interim analysis of one year data from IVAN trial comparing ranibizumab and bevacizumab in wet AMD presented at conference
Source: National Institute for Health Research - Service, Delivery and Organisation programme
Area: News
The first year results from an NIHR Health Technology Assessment (HTA) programme funded trial, IVAN (inhibit VEGF in age related choroidal neovascularisation), have been presented at the annual meeting of the Association for Research in Vision and Ophthalmology and are due to be published in the journal Ophthalmology. The trial is comparing ranibizumab (Lucentis) with bevacizumab (Avastin) in 610 subjects with wet age-related macular degeneration (wet AMD) from 23 hospitals and academic institutions in the UK. They received injections of the drug into the affected eye every month for the first three months. Groups were then subdivided to receive either injections at every visit thereafter or only if the specialist decided there was persistent disease. The project's lead researcher said: "The IVAN results at the end of the first year show that Lucentis and Avastin have similar effectiveness. Regardless of the drug received, or treating monthly or as needed, sight in the ...
Area: News
The first year results from an NIHR Health Technology Assessment (HTA) programme funded trial, IVAN (inhibit VEGF in age related choroidal neovascularisation), have been presented at the annual meeting of the Association for Research in Vision and Ophthalmology and are due to be published in the journal Ophthalmology. The trial is comparing ranibizumab (Lucentis) with bevacizumab (Avastin) in 610 subjects with wet age-related macular degeneration (wet AMD) from 23 hospitals and academic institutions in the UK. They received injections of the drug into the affected eye every month for the first three months. Groups were then subdivided to receive either injections at every visit thereafter or only if the specialist decided there was persistent disease. The project's lead researcher said: "The IVAN results at the end of the first year show that Lucentis and Avastin have similar effectiveness. Regardless of the drug received, or treating monthly or as needed, sight in the ...
New Advances In Treating Inherited Retinal Diseases
Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers...
Topical Aganirsen Found To Be Active In Retinal Disease
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, has announced that positive data from a study of aganirsen (GS-101, eye drops) in a nonhuman primate model of choroidal neovascularization has been presented at the 2012 ARVO Annual Meeting in Fort Lauderdale, Florida...
Bill Would Repeal SGR, Phase Out Medicare Fee-for-Service
The proposal would pay for the payment overhaul with savings from the military pullback in Afghanistan and Iraq, making it even more of a long shot in a highly partisan election year.
Medscape Medical News
Medscape Medical News
Retinal Microchip Restores Vision in Retinitis Pigmentosa
A subretinal microchip technology appears to restore "useful" vision to patients with retinitis pigmentosa, but long-term studies are still needed.
Medscape Medical News
Medscape Medical News
New Study Also Finds AMD Agents Equal (CME/CE)
(MedPage Today) -- A head-to-head comparison between bevacizumab (Avastin) and ranibizumab (Lucentis) for wet age-related macular degeneration adds to mounting evidence that both agents are equals in improving visual acuity, British researchers reported.
Iluvien Gains Ground
Iluvien receives further European approval for the treatment of diabetic macular edema. It has yet to be approved in the U.S. Iluvien is an injected sustained release system.
Human Gene Therapy highlights new advances in human retinal disease
Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Metformin For Diabetes May Treat Uveitis, A Leading Cause Of Blindness
University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness...
Genetic Predictor For Fuchs’ Corneal Dystrophy Confirmed By Mayo Clinic
Mayo Clinic and University of Oregon researchers have confirmed that a genetic factor called a repeating trinucleotide is a strong predictor of an individual's risk of developing the eye condition Fuchs' dystrophy. The findings were presented at the annual conference of the Association for Research in Vision and Ophthalmology in Orlando, Fla...
New EHR Requirements Will Deter Use, Say Medical Societies
The American Medical Association and 98 other medical societies say CMS should survey physicians about its meaningful use incentive program before raising the performance bar.
Medscape Medical News
Medscape Medical News
New EHR Requirements Will Deter Use, Say Med Societies
The AMA and 98 other medical societies say CMS should survey physicians about its meaningful-use incentive program before raising the performance bar.
Medscape Medical News
Medscape Medical News
Iluvien® approved by the MHRA for chronic diabetic macular oedema
Source: BioSpace
Area: News
According to BioSpace, the MHRA has approved Iluvien® (intravitreal insert releasing fluocinolone acetonide for up to 36 months) for the treatment of vision impairment associated with chronic diabetic macular oedema considered insufficiently responsive to available therapies. This marketing authorisation follows the recently announced approval in Austria. These approvals were preceded by completion of the Decentralized Regulatory Procedure (DCP) in the EU, in which the MHRA, serving as the Reference Member State (RMS), delivered a positive outcome for Iluvien® along with six Concerned Members States, specifically Austria, France, Germany, Italy, Spain and Portugal. Additional marketing authorisations are expected in the coming months and Alimera continues to expect Iluvien® to be available in the EU by the end of 2012.
Area: News
According to BioSpace, the MHRA has approved Iluvien® (intravitreal insert releasing fluocinolone acetonide for up to 36 months) for the treatment of vision impairment associated with chronic diabetic macular oedema considered insufficiently responsive to available therapies. This marketing authorisation follows the recently announced approval in Austria. These approvals were preceded by completion of the Decentralized Regulatory Procedure (DCP) in the EU, in which the MHRA, serving as the Reference Member State (RMS), delivered a positive outcome for Iluvien® along with six Concerned Members States, specifically Austria, France, Germany, Italy, Spain and Portugal. Additional marketing authorisations are expected in the coming months and Alimera continues to expect Iluvien® to be available in the EU by the end of 2012.
Subscribe
